This has led to FDA approval of topical ruxolitinib (marketed as JAK1- and JAK2-selective) and oral preparations of abrocitinib and upadacitinib (both JAK1-selective) for AD, as well as oral deucravacitinib (TYK2-selective) for plaque psoriasis. This evidence concerns the gene JAK1 and psoriasis vulgaris.